Oct 06, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Burixafor ( GPC-100 ) Phase 2 Trial in Multiple Myeloma Nears Key Readout ...
Oct 02, 2025 • Benzinga
NEUTRAL
Price Over Earnings Overview: Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )
In the current session, Bristol-Myers Squibb Inc. ( NYSE:BMY ) is trading at $45.73, after a 3.58% decrease. Over the past month, the stock decreased by 2.06%, and in the past year, by 15.25%. With performance like this, long-term shareholders are more likely to start looking into the company's ...
Oct 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.
Oct 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
Oct 02, 2025 • South China Morning Post
NEUTRAL
Chinese healthcare, biotech firms flock to Hong Kong for IPOs
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, ...
Oct 01, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.